45results about How to "Adequate dose" patented technology

An inhaler for medicament in powder form with an opening intended for inhalation. The powder medicament is arranged in the inhaler in a number of enclosures, each enclosure including a specific dose of medicament. A member is provided for enabling access to the dose of medicament. The member is arranged and designed such that it is able to be inserted inside the enclosure and establish at least one outlet passage, between the interior of the enclosure and the inhalation opening, through which outlet passage the medicament is delivered to the patient upon inhalation.

Disclosed herein are compositions and methods for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibitor (PPI) in a pharmaceutically acceptable carrier.

The present invention provides compositions and methods for relieving pain at a site in a human or animal in need thereof by administering at a discrete site in a human or animal in need thereof a dose of capsaicin in an amount effective to denervate a discrete site without eliciting an effect outside the discrete location, the dose of capsaicin ranging from 1 μg to 3000 μg.

A solution for sterilizing one or more hollow components of a device, such as a medical device, is provided. Ultraviolet radiation having one or more predominant wavelength(s) and a sufficient dose is generated and directed to an interior side of the hollow component(s). The predominant wavelength(s) is / are selected to harm one or more target organisms that may be present on the interior side. The ultraviolet radiation can be delivered by a structure that is periodically inserted and retracted into the hollow component. The structure can be configured to provide additional cleaning capability, such as suction, for removing matter that may be present in the hollow component.

The present application provides compositions comprising α-galactosidase A in combination with an active site-specific chaperone for the α-galactosidase A, and methods for treating Fabry disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an α-galactosidase A enzyme formulation. The present application also provides methods for treating Fabry disease using intravenous administration of 1-deoxygalactonojirimycin.

As described below, the present invention features methods for reprogramming somatic cells and related therapeutic compositions and methods.

The present invention relates to a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound or the mimic thereof may be administered by HDPA so that high doses of the active vitamin D compound or the mimic thereof can be administered to an animal without inducing severe symptomatic hypercalcemia. The invention also relates a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof in combination with one or more other therapeutic agents.

An electrochemical biosensor test strip with four new features. The test strip includes an indentation for tactile feel as to the location of the strips sample application port. The sample application port leads to a capillary test chamber, which includes a test reagent. The wet reagent includes from about 0.2% by weight to about 2% by weight polyethylene oxide from about 100 kilodaltons to about 900 kilodaltons mean molecular weight, which makes the dried reagent more hydrophilic and sturdier to strip processing steps, such as mechanical punching, and to mechanical manipulation by the test strip user. The roof of the capillary test chamber includes a transparent or translucent window which operates as a “fill to here” line, thereby identifying when enough test sample (a liquid sample, such as blood) has been added to the test chamber to accurately perform a test. The test strip may further include a notch located at the sample application port. The notch reduces a phenomenon called “dose hesitation”.

The invention provides a controller unit for controlling the emission of at least on photon emitted source, the controller unit includes a central processing unit pre-programmed with selectable pre-programmed photonic emission protocols. The photonic emission protocols include parameters for regulating photonic emission from photon emitting sources, with the protocols having a pulsed emission mode for about 30% of the duration of each protocol, and a continuous emission mode for about 70% of the duration of each protocol, with a pulse rate selected from a range of frequencies of between 120 Hz and 20,000 Hz when in the pulsed emission mode.

The present invention provides methods for increasing secretion of dopamine and other neurotransmitters and treating or reducing the incidence of diseases involving decreased secretion of dopamine and other neurotransmitters, e.g. Parkinson's disease, comprising administering to the subject a uridine or a source thereof, and compositions for treating or reducing an incidence of Parkinson's disease, comprising a uridine, a uridine monophosphate, or a source thereof.

The present invention provides compositions and methods for relieving pain at a site in a human or animal in need thereof by administering at a discrete site in a human or animal in need thereof a dose of capsaicin in an amount effective to denervate a discrete site without eliciting an effect outside the discrete location, the dose of capsaicin ranging from 1 μg to 3000 μg.

The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurological conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-diphenyl barbituric acid to enhance the bioavailability of 5,5-diphenyl barbituric acid and brain delivery of same.

The invention provides a washing machine and a control method thereof. The washing machine comprises a washing cylinder, a laundry detergent box set and a metering pump. The laundry detergent box set at least comprises a first laundry detergent box for storing first laundry detergent and a second laundry detergent box for storing second laundry detergent. The metering pump is configured in a way that during a washing phase of the washing program of the washing machine, the metering pump pumps the first laundry detergent from the first laundry detergent box to the washing cylinder, first mixed liquor formed by the first laundry detergent and laundry water in the washing cylinder is used for cleaning clothes for first preset time; after the cleaning operation in the first preset time is finished, the metering pump pumps the second laundry detergent from the second laundry detergent box to the washing cylinder, and second mixed liquor formed by the second laundry detergent and the first mixed liquor is used for cleaning the clothes for second preset time. When the washing machine cleans fabrics, the decontamination effect is good, and the fabrics do not fade.

The invention discloses a compound magnesium sulphate wet packing and a preparation method thereof. The compound magnesium sulphate wet packing consists of 20 to 50 percent of magnesium sulphate, 0.1 to 4 percent of lidocaine, the balance being surplus water for injection and medical carrier. The preparation method comprises the steps of soaking the medical carrier in compound magnesium sulphate solution for thirty to sixty minutes after being made into sheets and being disinfected and sterilized, sterilizing the medical carrier with steam for thirty to forty-five minutes, and then putting the medical carrier into a plastic bag to be sealed and packed to prepare the compound magnesium sulphate wet packing. The compound magnesium sulphate wet packing can effectively prevent chemotherapy phlebitis; and the clinical trials show that through the compound magnesium sulphate wet packing, the effective rate of caring and treating swelling and pain caused by edema on local subcutaneous tissue when chemotherapy drugs are instilled in the vein of the patient is over 90 percent, thereby reducing the pain of the patient effectively and improving the quality of life of the patient.

The invention relates to sterilized magnesium sulfate wet dressing agent. It is formed by medical using magnesium sulfate aqueous solution and carrier. The former accounts for 20-50wt%, and can be made by high temperature sterilizing after sand stick filtering with 0.50-0.80mum aperture. The latter can be the water absorption paper towel, gauze, or medical using dressing. It can be used to cure local subcutaneous tissue swelling ache. The using method includes the following steps: dressing it along the vein direction, changing for every 30-60min until to the dripping off, stopping the wet dressing after withdrawing the needle for 1-2h. The user can understand clearly through the direction for use on the packaging bag which can solve the problems of carryover, using inconvenient, and infection.

A method for alignment mark preservation includes a step of preparing a lower alignment mark structure on a substrate. In one configuration of the invention, the alignment mark structure includes a lower trench. In a further step, a hard mask coating is applied to a substrate that includes the alignment marks. Preferably, the hard mask material is an amorphous carbon material. In a further step, a selected portion of the hard mask located above the lower alignment mark structure is exposed to a dose of radiation. In one aspect of the invention, the surface of regions of the hard mask coating that receive the dose of radiation become elevated with respect to other regions of the hard mask surface. For those elevated regions of the hard mask that are aligned with an underlying alignment mark trench, the elevated regions serve as an alignment mark that preserves the original horizontal position of the underlying alignment mark.

The present invention relates to a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound or the mimic thereof may be administered by HDPA so that high doses of the active vitamin D compound or the mimic thereof can be administered to an animal without inducing severe symptomatic hypercalcemia. The invention also relates a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof in combination with one or more other therapeutic agents.

The present application provides for compositions comprising high concentrations of acid α-glucosidase in combination with an active site-specific chaperone for the acid α-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid α-glucosidase enzyme formulation.

The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurological conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-diphenyl barbituric acid to enhance the bioavailability of 5,5-diphenyl barbituric acid and brain delivery of same.

This invention relates, e.g., to a method for promoting CNS axon regeneration, comprising (1) inhibiting the expression or activity in a neuron of one or more of the members of the Krüppel-like transcription factor (KLF) family that suppress axon growth (e.g., KLF 1, 2, 3, 4, 5, 9, 12, 13, 14, 15 and / or 16), and / or (2) stimulating the expression or activity in a neuron of one or more of the members of the KLF family that promote axon growth (e.g., KLF 6 and / or 7).

Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.

The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w / v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

The invention relates to a medicine, and in particular relates to a medicine for treating rheumatoid bone diseases and a preparation method thereof. A medicine bag comprises the following medicines by weight: 10-15 g of szechuan lovage rhizome, 10-15 g of radix angelicae, 15-20 g of radix clematidis, 5-10 g of radix aconiti agrestis, 5-10 g of monkshood, 5-10 g of fructus liquidambaris, 10-15 g of cinnamon, 10-20 g of cortex acanthopanacis, 10-15 g of frankincense, 10-15 g of myrrh, 10-15 g of dried body of ground beetle, 10-15 g of Japanese snailseed root, 10-15 g of rhizoma acori graminei, 10-15 g of galangal, 15-20 g of ramulus rubi, 20-30 g of Tibetan hair cream, and 20-30 g of tinospora sinensis merr. The medicinal liquor comprises the following medicines by weight: 20-30 g of boschniakia rossica, 10-15 g of Tibetan saussurea involucrata, 10-15 g of saffron crocus, 20-30 g of fructus teminaliae billaricae, 20-30 g of Tibetan Fritillaria thun-bergli, 10-20 g of Tibetan lithospermum, and the balance of 60% alcoholic solution with the volume fraction of 500ml.

The present invention relates to a method for preventing, treating or ameliorating pulmonary disorders in a patient receiving a chemotherapeutic or radiotherapeutic agent or treatment comprising administering to the patient a pharmaceutical composition comprising an effective amount of active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound, or the mimic thereof, may be administered by HDPA so that high doses of the active vitamin D compound can be administered to an animal without inducing severe symptomatic hypercalcemia.

The present invention provides a charged particle beam device which can effectively restrain misalignment of an optical axis even if a position of an anode is changed. The present invention is a charged particle beam device comprising a cathode provided with a charged particle source which emits a charged particle, an anode which applies an electric field to the emitted charged particle, a charged particle beam deflector which deflects an orbit of a charged particle beam having passed the anode, and a charged particle beam detector which detects the charged particle beam from a sample to which the charged particle is irradiated, wherein a distance changing mechanism which changes a distance between the cathode and the anode, corresponding to a charged particle amount emitted from the charged particle source and a deflection amount control mechanism which detects a condition of the deflector under which the charged particle dose detected from the sample scanned by deflecting the charged particle beam in the changed distance becomes a desired size and controls deflection of the deflector at sample measurement on the basis of the condition are provided.